These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29102419)

  • 21. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of acute otitis media, recurrent otitis media and tympanostomy tube insertion in children after its implementation into the national immunization program in Turkey.
    Soysal A; Gönüllü E; Yıldız I; Aydemir G; Tunç T; Fırat Y; Erdamar B; Karaböcüoğlu M
    Hum Vaccin Immunother; 2020; 16(2):445-451. PubMed ID: 31424317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2014 Dec; 59(12):1724-32. PubMed ID: 25159581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the Seven-valent Pneumococcal Conjugate Vaccine on Acute Otitis Media in Japanese Children: Emergence of Serotype 15A Multidrug-resistant Streptococcus pneumoniae in Middle Ear Fluid Isolates.
    Ozawa D; Yano H; Endo S; Hidaka H; Kakuta R; Okitsu N; Kanamori H; Ogawa M; Ichimura S; Shimojima M; Inomata S; Kaku M; Katori Y
    Pediatr Infect Dis J; 2015 Sep; 34(9):e217-21. PubMed ID: 26083590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of first year of life acute otitis media admissions before and after the 13-valent pneumococcal conjugate vaccine.
    Marom T; Israel O; Gavriel H; Pitaro J; Baker AA; Eviatar E
    Int J Pediatr Otorhinolaryngol; 2017 Jun; 97():251-256. PubMed ID: 28483246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
    Robberstad B; Frostad CR; Akselsen PE; Kværner KJ; Berstad AK
    Vaccine; 2011 Nov; 29(47):8564-74. PubMed ID: 21945264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changing trends of acute otitis media bacteriology in central Israel in the pneumococcal conjugate vaccines era.
    Tamir SO; Roth Y; Dalal I; Goldfarb A; Grotto I; Marom T
    Pediatr Infect Dis J; 2015 Feb; 34(2):195-9. PubMed ID: 25741972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media.
    Revai K; McCormick DP; Patel J; Grady JJ; Saeed K; Chonmaitree T
    Pediatrics; 2006 May; 117(5):1823-9. PubMed ID: 16651345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: Effects of the seven-valent pneumococcal conjugate vaccine.
    Suga S; Chang B; Asada K; Akeda H; Nishi J; Okada K; Wakiguchi H; Maeda A; Oda M; Ishiwada N; Saitoh A; Oishi T; Hosoya M; Togashi T; Oishi K; Ihara T
    Vaccine; 2015 Nov; 33(45):6054-60. PubMed ID: 26235372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States.
    Zhou X; de Luise C; Gaffney M; Burt CW; Scott DA; Gatto N; Center KJ
    Int J Pediatr Otorhinolaryngol; 2019 Apr; 119():96-102. PubMed ID: 30690309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Miron D; Aviner S; Dagan R;
    Vaccine; 2016 Aug; 34(38):4543-4550. PubMed ID: 27475471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2021 Feb; 17(2):517-526. PubMed ID: 32574101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of pneumococcal conjugated vaccines on occurrence of recurrent acute otitis media among infants diagnosed with acute otitis media at an age younger than 2 months.
    Ziv O; Adelson D; Sadeh R; Kordeluk S; El-Saied S; Leibovitz E; Kraus M; Kaplan D
    Eur J Pediatr; 2023 Jun; 182(6):2873-2879. PubMed ID: 37052673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database.
    Yanai T; Yoshida S; Takeuchi M; Kawakami K
    Vaccine; 2023 Jun; 41(29):4313-4318. PubMed ID: 37286407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2016 Sep; 63(5):611-8. PubMed ID: 27225239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
    Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ambulatory Visits for Otitis Media before and after the Introduction of Pneumococcal Conjugate Vaccination.
    Kawai K; Adil EA; Barrett D; Manganella J; Kenna MA
    J Pediatr; 2018 Oct; 201():122-127.e1. PubMed ID: 29958675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pneumococcal conjugate vaccines for preventing otitis media.
    Jansen AG; Hak E; Veenhoven RH; Damoiseaux RA; Schilder AG; Sanders EA
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001480. PubMed ID: 19370566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine.
    McEllistrem MC; Adams JM; Patel K; Mendelsohn AB; Kaplan SL; Bradley JS; Schutze GE; Kim KS; Mason EO; Wald ER
    Clin Infect Dis; 2005 Jun; 40(12):1738-44. PubMed ID: 15909260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
    Galanis I; Lindstrand A; Darenberg J; Browall S; Nannapaneni P; Sjöström K; Morfeldt E; Naucler P; Blennow M; Örtqvist Å; Henriques-Normark B
    Eur Respir J; 2016 Apr; 47(4):1208-18. PubMed ID: 26797033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.